Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Longevity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Longevity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-001391-42 Sponsor Protocol Number: Speed-Covid Start Date*: 2021-05-12
    Sponsor Name:Medical University of Graz
    Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study
    Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000877-10 Sponsor Protocol Number: MWTBTXA Start Date*: 2021-07-14
    Sponsor Name:Bispebjerg Hospital, Department of Dermatology
    Full Title: Longevity of microwave thermolysis and botulinum toxin A for treatment of axillary hyperhidrosis: a randomized intra-individual trial
    Medical condition: Axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002363-22 Sponsor Protocol Number: IIV-482 Start Date*: 2021-05-27
    Sponsor Name:National Institute for Public Health and the Environment
    Full Title: Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study)
    Medical condition: SARS-CoV-19, frailty
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003573-58 Sponsor Protocol Number: 2025 Start Date*: 2021-08-09
    Sponsor Name:Antwerp University Hospital
    Full Title: Vaccination against cOvid-19 In CancEr: booster shot BNT161b2 vaccine after full vaccination with ChAdOx1-S vaccine (Tri-VOICE plus)
    Medical condition: Onco-hematological patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000300-38 Sponsor Protocol Number: 001610 Start Date*: 2021-02-05
    Sponsor Name:Antwerp University Hospital
    Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE)
    Medical condition: Onco-hematological patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002965-19 Sponsor Protocol Number: 1 Start Date*: 2005-03-14
    Sponsor Name:Orthopaedic department, Karolinska Institutet, Danderyd's Hospital
    Full Title: Can risedronate prevent periprosthetic bone loss after hip arthroplasty? A randomized, double-blind, placebo-controlled trial
    Medical condition: Periprosthetic bone loss after total hip arthroplasty (THA) is the main factor in limiting the longevity of implants used för treatment of osteoarthritis. Bone loss leads to implant destabilization...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002613-34 Sponsor Protocol Number: NL76336.041.21 Start Date*: 2021-06-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prospective monitoring of antibody response following COVID-19 vaccination in patients with Down Syndrome
    Medical condition: Persons with Down syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003388-90 Sponsor Protocol Number: PB21VAC Start Date*: 2021-07-05
    Sponsor Name:Princess Máxima Center for Pediatric Oncology
    Full Title: Prospective monitoring of immune response following COVID-19 vaccination in children with cancer
    Medical condition: Children with cancer, receiving COVID-19 vaccination
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000256-33 Sponsor Protocol Number: Ra-P-OCD-01 Start Date*: 2019-06-27
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement
    Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000836-24 Sponsor Protocol Number: IIV-406 Start Date*: 2019-06-19
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults.
    Medical condition: Healthy volunteers above 25 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000382-16 Sponsor Protocol Number: 1063-Dara-H-VERUMM Start Date*: 2021-04-07
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination with bortezomib-dexamethasone ...
    Medical condition: Relapsed and refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000872-13 Sponsor Protocol Number: 202000865 Start Date*: 2021-03-02
    Sponsor Name:University Medical Center Groningen
    Full Title: Vaccination against cOvid In CancEr
    Medical condition: solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000673-83 Sponsor Protocol Number: TJB2101 Start Date*: 2021-03-11
    Sponsor Name:CHU de Liège
    Full Title: Impact of the immune system on response to COVID-19 vaccine in allogeneic stem cell recipients
    Medical condition: Allogeneic hematopoietic stem cell recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005492-25 Sponsor Protocol Number: PrEP-CS-003 Start Date*: 2016-03-10
    Sponsor Name:PrEP Biopharm Ltd.
    Full Title: A phase IIa, randomised, double-blind, placebo-controlled study using outpatient setting to investigate the duration of effect and evaluate further safety of PrEP-001 given prophylactically in heal...
    Medical condition: Human Rhinovirus (HRV-16)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10075163 Human rhinovirus test PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003250-41 Sponsor Protocol Number: 1 Start Date*: 2015-09-15
    Sponsor Name:Public Health England
    Full Title: Protection induced by Live Attenuated Influenza Vaccine (LAIV or Fluenz Tetra) - applied epidemiological study
    Medical condition: There is no medical condition associated with this trial. The trial involves vaccination of healthy children with a licensed product according to the SmPC. The vaccination is Fluenz Tetra, a live...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016794 Flu vaccination LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002134-74 Sponsor Protocol Number: FLU-v004 Start Date*: 2016-07-27
    Sponsor Name:PepTcell Limited (trade name SEEK)
    Full Title: Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model
    Medical condition: Influenza virus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003699-34 Sponsor Protocol Number: QA343 Start Date*: 2012-03-02
    Sponsor Name:London School of Hygiene & Tropical Medicine
    Full Title: Feasibility study including a double blind (C)controlled study and an open label (C) controlled study for a larger randomised trial measuring the effect of oral vitamin D (I) on morbidity and morta...
    Medical condition: The aim of vitamin D supplementation is to increase circulating 25(OH) vitamin D level in the general population. The aim of the main trial for which this is a feasibility study is to determine whe...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004296-77 Sponsor Protocol Number: BTA585-003 Start Date*: 2016-02-08
    Sponsor Name:Biota Pharma Europe Limited
    Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral...
    Medical condition: Respiratory Syncytial Virus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004042-26 Sponsor Protocol Number: PrEP-CS-002 Start Date*: 2015-11-17
    Sponsor Name:hVIVO Services Limited
    Full Title: A Phase II, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Asthmatic Subjects Subsequently Challenged with Human Rhinoviru...
    Medical condition: Human Rhinovirus (HRV-16)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10075163 Human rhinovirus test PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004953-26 Sponsor Protocol Number: BHS-TC13 Start Date*: 2016-03-11
    Sponsor Name:Ghent University Hospital
    Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:26:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA